Rejection Of AstraZeneca Lawsuit May Have Considerable Impact On Remaining Cases

The Third Circuit Court of Appeals’ rejection of AstraZeneca’s lawsuit this month alleging the Inflation Reduction Act’s Medicare drug price negotiation program violates the drug maker’s due process could set a precedent for several other cases that allege the implementation of price negotiations invokes a taking of a drug company’s private patented products, violating the Fifth amendment Takings clause.